Medexus Pharmaceuticals Inc. (MEDXF)
OTCMKTS · Delayed Price · Currency is USD
2.049
-0.009 (-0.44%)
Oct 29, 2025, 1:04 PM EDT
Medexus Pharmaceuticals Revenue
Medexus Pharmaceuticals had revenue of $24.62M in the quarter ending June 30, 2025, a decrease of -9.78%. This brings the company's revenue in the last twelve months to $105.66M, down -2.87% year-over-year. In the fiscal year ending March 31, 2025, Medexus Pharmaceuticals had annual revenue of $108.33M, down -4.18%.
Revenue (ttm)
105.66M
Revenue Growth
-2.87%
P/S Ratio
0.64
Revenue / Employee
1.16M
Employees
91
Market Cap
67.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 108.33M | -4.72M | -4.18% |
| Mar 31, 2024 | 113.05M | 4.96M | 4.59% |
| Mar 31, 2023 | 108.10M | 31.40M | 40.93% |
| Mar 31, 2022 | 76.70M | -2.96M | -3.71% |
| Mar 31, 2021 | 79.66M | 24.15M | 43.52% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Medexus Pharmaceuticals News
- 4 weeks ago - Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors - Newsfile Corp
- 4 weeks ago - Medexus Pharmaceuticals Inc. (MDP:CA) Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 2 months ago - Medexus Pharmaceuticals Inc. (MEDXF) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection - Newsfile Corp
- 3 months ago - Medexus Schedules First Fiscal Quarter 2026 Conference Call - Newsfile Corp
- 3 months ago - GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026 - Newsfile Corp
- 4 months ago - Medexus Pharmaceuticals Inc. (MEDXF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States - Newsfile Corp